Research And Markets: Comprehensive Coverages Of The R&D Trends To Set The Future Leukemia Marketplace.

DUBLIN, Ireland -- Leukemia includes a broad variety of histological separate disorders. This make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry.

Research and Markets (http://www.researchandmarkets.com/reports/c8479) has announced the addition of Competition on the Future Leukemia Markets to their offering

This has now clearly changed with the launch of Novartis' second-line therapy Gleevec (imatinib mesylate) for chronic myeloid leukemia (CML), presenting the industry with proof that development within the leukemia market produces lucrative returns. Gleevec saw sales rise 47 percent to $757 million in the first half 2004. Consequently, the historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Additional progress in disease molecular pathology, and research into the possible significance of innovative predictive markers will offer physicians with supplementary information with which to compose future treatment strategies.

To enable people to update their knowledge status at the same time receive a basic foundation, this report "Competition on the Future Leukemia Markets" describes and analyzes the latest year of progress in four different market segments; CLL, CML ALL and AML. In this report, we provide one of the most comprehensive coverages of the R&D trends to set the future leukemia marketplace. This report presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions of drugs and targets. There are 35 drug candidates identified in phase II or III stage of development. Among these drugs it can clearly be seen that there is substantial progress while others have failed. There will soon be a harder competition in several of the leukemic sub-markets and current treatments will be changed for the benefit of more innovative therapies.

The information structure in this cancer highlight reports will as well provide an easy reading format to track B2B collaborations and industry academic relationships.

Therapeutic candidates included in this analysis: AG-858, AP23573, Avastin, Atragen, BAY 43-9006, Bryostatin-1, Campath, Ceplene, CEP-701, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Genasense, Gleevec, GVAX, Mylotarg, Multiferon, OSI-461, Phenoxodiol, pentostatin, PEG-Interferon, PKC412, PTK787, Revlimid, Rituxan, SU5416, SCH 54031, Sarasar, Triapine, Tezacitabine, Troxacitabine, Trisenox, valspodar, Velcade, Zamyl, Zarnestra, Xcytrin, XL999

For more information visit http://www.researchandmarkets.com/reports/c8479